ArticleCardiovascular diabetology2022

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.

Yi-Hsin Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.